– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets – – Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology...
Coherus Oncology: Q2 Earnings Snapshot
– LOQTORZI ® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – – Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck...
REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (Nasdaq: CHRS), today announced that its second quarter 2026 financial results will be released on Wednesday, August...
REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. (“Zumutor”), an immuno-oncology biotech company, today announced a clinical...
EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:ARTV),(NASDAQ:FATE),(NASDAQ:IBRX),(NASDAQ:CHRS) EQNX::TICKER_END
Coherus Oncology (NASDAQ:CHRS) said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through the rest of 2026, while the company prepares for multiple clinical data readouts...
Coherus Oncology: Q1 Earnings Snapshot
– LOQTORZI ® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking...
REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (Nasdaq: CHRS), today announced that its first quarter 2026 financial results will be released after market close on Monday,...